Pre-market top loser: ADXN.SW Addex down 9.03% to CHF0.0504: outlook
Pre-market trading shows ADXN.SW stock sliding 9.03% to CHF0.0504, marking it among the top losers on the SIX exchange this session. The move follows a heavier-than-average volume of 329,067 shares versus a 50-day average of 176,328, signaling active selling. Addex Therapeutics Ltd (ADXN.SW) remains a small-cap biotech with negative EPS (-0.06) and a market cap near CHF7.60 million, so volatility is expected. We review valuation, technical setup, catalysts, and Meyka AI’s forecast to frame near-term risk and opportunity.
ADXN.SW stock: pre-market price action and drivers
ADXN.SW stock opened at CHF0.0550 and is trading at CHF0.0504, down -9.03% from the previous close of CHF0.0554. Volume is elevated at 329,067 versus the average 176,328, giving the drop conviction. The stock is near its year low CHF0.0472 and well below its year high CHF0.0850, which frames the current move as continuation of recent weakness.
ADXN.SW stock: fundamentals and valuation
Addex Therapeutics (ADXN.SW) is a development-stage biotechnology firm listed on SIX in Switzerland with focus on CNS allosteric modulators. Key ratios show EPS -0.06 and PE -0.84, reflecting negative earnings. Book value per share is CHF0.05288, and price-to-book sits near 0.95, suggesting the market prices the company close to its book value while revenues are minimal and price-to-sales reads ~54.84.
ADXN.SW stock: technicals and liquidity
Technicals show an RSI 39.23 and ADX 42.37, indicating a strong trend and near-oversold momentum. Bollinger bands tighten around CHF0.05, while on-balance volume is negative and relative volume is ~1.87, confirming heavier selling. Average 50- and 200-day prices are CHF0.05517 and CHF0.05836, respectively, both above today’s price.
ADXN.SW stock: catalysts, risks and sector context
Near-term catalysts include the company’s pipeline updates and the scheduled earnings announcement on 2026-03-09. Risks are typical for small biotechs: clinical setbacks, funding dilution, and thin coverage. The Healthcare sector on SIX trades stronger year-to-date, so ADXN.SW’s weakness is idiosyncratic and likely tied to company-specific news or positioning rather than sector-wide flows.
ADXN.SW stock: Meyka AI grade and rationale
Meyka AI rates ADXN.SW with a score of 63.38 out of 100 — Grade B, Suggestion: HOLD. This grade factors S&P500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. The neutral stance reflects very small market cap, mixed valuation signals, and limited revenue but acceptable liquidity and book value coverage. These grades are informational and not investment advice.
ADXN.SW stock: Meyka AI forecast and price targets
Meyka AI’s forecast model projects monthly CHF0.05, quarterly CHF0.10, and yearly CHF0.04104. Versus the current price CHF0.0504, the yearly projection implies an ~18.56% downside and the quarterly projection implies an ~98.41% upside. Forecasts are model-based projections and not guarantees. Practical price targets for traders: a conservative floor CHF0.0472 (year low), base target CHF0.0600, and bull target CHF0.1000, tied to clinical progress or partnerships.
Final Thoughts
ADXN.SW stock is the session’s pre-market laggard on SIX, down 9.03% to CHF0.0504 on elevated volume. Fundamentals show negative earnings (EPS -0.06) and a market cap of CHF7,603,944, while book value per share near CHF0.05288 keeps valuation close to tangible equity. Technical indicators (RSI 39.23, ADX 42.37) point to a strong downtrend but near-oversold conditions. Meyka AI rates ADXN.SW 63.38/100 (B, HOLD) and its model yields a yearly projection of CHF0.04104, implying ~18.56% downside from today’s price, though a quarterly model spike to CHF0.10 shows how binary biotech outcomes can flip returns. For traders, focus on upcoming clinical or corporate news and monitor volume; for longer-term holders, fund runway and dilution risk matter most. Meyka AI, our AI-powered market analysis platform, flags ADXN.SW as a high-volatility, event-driven name where tight risk controls and clear entry triggers are essential.
FAQs
Why is ADXN.SW stock falling pre-market today?
ADXN.SW stock is down pre-market due to higher-than-average selling and thin market cap exposure. Elevated volume (329,067) versus the 50-day average suggests position adjustment or reaction to company-specific news rather than sector weakness.
What is Meyka AI’s forecast for ADXN.SW stock?
Meyka AI’s forecast model projects monthly CHF0.05, quarterly CHF0.10, and yearly CHF0.04104. These are model-based projections and not guarantees; the yearly figure implies about -18.56% from the current CHF0.0504 price.
What are the main risks for ADXN.SW stock holders?
Key risks include clinical trial setbacks, funding needs and potential dilution, limited revenue, and low market cap liquidity. Addex’s negative EPS (-0.06) highlights continued development-stage losses.
What price levels should traders watch for ADXN.SW stock?
Traders should watch the year low CHF0.0472, short-term resistance near CHF0.0550, and the base target CHF0.0600. Breaks below CHF0.0472 could signal further downside; strong news could push toward CHF0.10.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
